Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Study Details
Study Description
Brief Summary
Multicenter, open-label, parallel-group, phase II randomized study in patients with oligometastatic prostate cancer with 1-3 asymptomatic metastases of the soft tissue or bone. Eligible patients will be randomized at 1:1 ratio to Stereotactic Radiotherapy followed by Lu-PSMA (arm A) or Stereotactic Radiotherapy (arm B)
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Biochemical recurrence (BCR), i.e. prostate-specific antigen (PSA) only recurrence occurs in nearly one-third of patients, after primary definitive therapy for prostate cancer.
PSMA (prostate-specific membrane antigen) is an attractive target for diagnosis and therapy of metastasized prostate cancer (PCa) as its expression levels are directly correlated with androgen independence, metastases and progression.
Positron Emission Tomography/Computed Tomography (PET-CT) using PSMA is able to detect > 50% of relapses with PSA between 0.50 and 1 ng/mL and >75% with PSA between 1 and 2.
Oligometastatic prostate cancer include 1-3 asypmtomatic metastatic lesion(s) of the soft tissue or bone. The treatment of oligometastatic disease depends on multiple factors including the site, the size, number and location of metastases, and the effectiveness of treatments.
Recent advances in radiation therapy allow to image and treat precisely target lesions within any anatomic region of the body. Stereotactic radiation therapy permit highly conformal and precisely targeted radiation administered in a dose intensive strategy. Local control in excess of 75% has been reported for metastatic prostate cancer with very low toxicity.
Lutetium 177-PSMA (177Lu-PSMA) is the most extensively investigated PSMA radioligand for radionuclide therapy in castration resistant prostate cancer (CRPC). Several retrospective studies and three phase II prospective studies demonstrated safety and impressive efficacy of 177Lu-PSMA in metastatic CRPC (mCRPC).The purpose of this study is to evaluate in a randomized phase II study the impact of Lu-PSMA added to stereotactic radiotherapy vs radiotherapy alone in PSMA detected- metastatic lesions of hormone-sensible prostate cancer.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Stereotactic Radiotherapy followed by Lu-PSMA (arm A) Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen. 177Lu-PSMA-I&T in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 Gigabecquerel (GBq) |
Drug: [177Lu]Lu-PSMA I&T
The radiopharmaceutical 177Lu-PSMA-I&T will be administered, by slow intravenous injection, in 2 cycles of treatment at 6-8 weekly intervals at a dosage of 7.4 GBq.
Other Names:
Radiation: Stereotactic Radiotherapy
Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
Other Names:
|
| Active Comparator: Stereotactic Radiotherapy (arm B) Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen. |
Radiation: Stereotactic Radiotherapy
Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen, depending on the target size and the surrounding normal tissue constraints,
Other Names:
|
Outcome Measures
Primary Outcome Measures
- 12-month PSA (Prostate-Specific Antigen)-progression-free survival (PSA-PFS) [12-months]
To determine the proportion of men with oligometastatic hormone sensitive prostate cancer who have PSA progressed after 12 months from randomization to Stereotactic Radiotherapy and Lu-PSMA versus Radiotherapy alone.
Secondary Outcome Measures
- 12-month radiographic Progression-free survival (rPFS), Androgen Deprivation Therapy-Free survival (ADT-FS) and Total progression-free survival (PSA-PFS+rPFS) [12-months]
To assess radiographic progression free survival (PFS) after 12 months, ADT free survival (ADT-FS) and Total progression-free survival (PSA-PFS+rPFS) of Lu-PSMA + Stereotactic Radiotherapy vs Stereotactic Radiotherapy defined as the time interval between the day of randomization and the day of disease progression.
- Incidence of Treatment-Emergent Adverse Events [Toxicity] [60 months]
To describe the toxicity of Lu-PSMA + Stereotactic Radiotherapy vs Stereotactic Radiotherapy for the population enrolled using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
- Overall survival (OS) [60 months]
To assess overall survival (OS) defined as the time interval between the day of randomization and death or last contact.
- Proportion of subjects with undetectable PSA (<0.2 ng/mL) [60 months]
To assess proportion of subjects with undetectable PSA (<0.2 ng/mL) defined as a PSA level ≤0.20 ng/mL as measured during routine follow-up
- Quality of life questionnaire (QLQ) [60 months]
To assess quality of life in the Lu-PSMA+ Stereotactic Radiotherapy arm vs Stereotactic Radiotherapy only arm using the Brief Pain Inventory form. The scale ranging from 0-10, where 0 is labeled 'No pain,' and 10 is labeled 'Worst pain imaginable'.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients must have 1-3 asymptomatic metastatic tumor(s) of the soft tissue or bone developed within the past 3-months that are ≤ 5.0 cm or < 250 cm3 documented at CT or Whole Body-Diffusion (WBD)-MRI.
-
PSMA-PET/CT positive scan matching with lesions documented on baseline CT or WBD-MRI.
-
Patients must have had their primary tumor treated with surgery and/or radiation and previous salvage radiation to the prostate bed or pelvis is allowed.
-
Patients will be admitted to therapeutic phase only if the semi quantitative intensity of lesions uptake at the diagnostic PET/CT PSMA is higher than that of salivary glands or Standardized uptake value (SUV) has to be 1.5 times higher than the average total body.
-
Histologic confirmation of malignancy (primary or metastatic tumor).
-
Prostate specific antigen (PSA) ≥ 0.2 ng/mL but ≤ 50 ng/mL and Testosterone ≥ 125 ng/dL.
-
PSA doubling time (PSADT) < 15 months. PSADT will be calculated using as many PSA values that are available from time of relapse (PSA > 0.2 ng/dL).
-
Patients unfit or refusing ADT.
-
Patients may have had prior systemic therapy and/or ADT associated with treatment of their primary prostate cancer. Patients may have had ADT associated with salvage radiation therapy.
-
Patients must be ≥ 18 years of age.
-
Patient understands the purpose of the study and the procedures required for it; the patient is willing to participate in the study and to sign a written informed consent document.
-
Patients must have an Eastern Cooperative Oncology Group performance status ≤ 2.
-
Patients should have a life expectancy of at least 6 months.
-
Patients must have normal organ and marrow function.
-
If the participant engages in sexual activity with a woman of childbearing potential, a condom must be used together with another highly effective method of contraception during the Treatment Period and for 3 months after the last dose of study intervention. The participant must agree not to donate sperm for the purpose of reproduction during the Treatment Phase and for a minimum of 3 months after receiving the last dose of study intervention.
-
Highly effective birth control methods are required beginning at the screening visit and continuing until 6 months following last treatment with study drug. Patients and female partner who is of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception, starting at screening and continuing throughout the study period and for 6 months after final study drug administration.
Exclusion Criteria:
-
No more than 3 years of ADT is allowed, with the most recent ADT treatment having occurred more than 6 months prior to enrollment.
-
PSMA -PET/CT scan within the past 3 months with lesions not seen on baseline CT or WBD-MRI.
-
Spinal cord compression or impending spinal cord compression.
-
Suspected pulmonary and/or liver metastases.
-
Bone metastasis in a femoral bone.
-
Previous radiation therapy on the metastatic site.
-
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
-
Participation in another clinical trial with any investigational agents within 30 days prior to study screening.
-
Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant.
-
Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177-Lu-PSMA- I&T or other agents used in the study.
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
-
Unable to lie flat during or tolerable SABR (Ablative stereotactic radiotherapy)
-
Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 5 years (except for previously treated basal cell carcinoma and in situ carcinoma of the uterine cervix);
-
HIV-positivity, whether or not symptomatic.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Investigators
- Principal Investigator: Federica Matteucci, UO Medicina Nucleare, IRCCS IRST
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRST185.09